Trending Now
The Next Chapter for the Metaverse Investment Story isn’t about Tech...
The metaverse theme has been largely a technology investing theme thus far. But the next chapter for market participants is likely to...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Cyclacel Pharmaceuticals (NASDAQ: CYCC) Sees Significant Stock Volatility Amid New Financing...
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a prominent biopharmaceutical company focused on the development of innovative cancer therapies, recently witnessed significant stock price...
MAKE IT MODERN
LATEST REVIEWS
Will Silo Pharma Inc (SILO) keep surging post entering Exclusive Global...
Sarasota, FL – July 16, 2024 – Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has today announced a significant...
MAKE IT MODERN
PERFORMANCE TRAINING
Sutro Biopharma Inc (NASDAQ:STRO) Applauds The Encouraging STRO-002 Interim Phase 1 Clinical Data
Chief executives from Sutro Biopharma Inc (NASDAQ:STRO) will on Wednesday host a conference call. The company outlines that they will hold discussions in line...
Commodity Price Shock Could Fuel New Boom in Green Tech Stocks (BLDP, ECOX, NIO,...
As commodity prices skyrocket higher following Russia’s invasion of Ukraine, attention in the markets is turning toward sustainability plays. The ideas are...
Sorrento Therapeutics Inc (NASDAQ: SRNE) Recently Issued an Update of Its STL 919 Study
Sorrento Therapeutics Inc (NASDAQ: SRNE) recently updated its recent study to its shareholders. The company announced that it recruited fit volunteers. Moreover, the study...
Aptose Biosciences (NASDAQ:APTO) Announce Dosing of First AML Patient In CG-806 Study
Aptose Biosciences Inc. (NASDAQ:APTO) has announced the dosing of the first acute myeloid leukemia (AML) patient in Phase 1 a/b CG-806 clinical study.
CG-806 inhibits...
Ovid Therapeutics Inc. (NASDAQ:OVID) Halts NEPTUNE Study Of OV101 After Failing To Achieve Primary...
Ovid Therapeutics Inc. (NASDAQ:OVID) has a reported topline data from its third phase NEPTUNE clinical study of OV101 (gaboxadol) in Angelman syndrome treatment.
NEPTUNE study...
MAKE IT MODERN
